TRPM4 in Bladder Cancer: Prognostic Gene Risk Model and Drug Sensitivity

Qi Zhao's 2026 study integrates single-cell and transcriptome data to explore TRPM4's role in bladder cancer. The dataset includes 220 candidate genes, a six-gene risk model, immune infiltration analysis of 12 cell types, and drug sensitivity results for 112 compounds. It is a 116.8 KB Excel file licensed under CC-BY-4.0.

Use Cases

• Building prognostic risk models based on the six identified marker genes (UNC93B1, FAM193B, POGLUT3, FBN1, MAP1B, RUNX2).
• Analyzing immune cell infiltration patterns based on the 12 distinct immune cell types identified.
• Investigating drug sensitivity differentials based on the analysis of 112 drugs, including WZ3105.
• Performing gene set enrichment analysis based on pathways like the melanoma pathway mentioned in the description.

Strengths

• Includes results from a multi-omics integration of single-cell and whole-genome transcriptomic data.
• Identifies a specific six-gene prognostic risk model and 220 candidate genes.
• Contains analyses for 12 immune cell types and sensitivity results for 112 drugs.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

figshare

Collection Method

Integrated analysis of single-cell and transcriptomic data.

Time Range

null

Freshness

Last updated 2026-04-13 05:21:48; freshness should be verified.

Geography

null